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Divergent total synthesisa b s t r a c t
Divergent strategy in natural product synthesis allows the comprehensive synthesis of family natural
products. Efﬁcient formulation of this idea requires the biosynthetic/biosynthesis-inspired insight toward
the well-orchestrated design of a pluripotent late-stage intermediate, in concomitant with the applicabil-
ity of the intermediates for versatile transformations. This digest focuses on the actual applications of
those strategies in natural product synthesis with an emphasis on the recipes for the choice of the com-
mon intermediates.
 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license
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Chemists have often made an analogy of natural product total
synthesis with climbing the mountain. During the climbing, one
has to ﬁnd out a mountain path that you believe would go to the
summit of the heap. By trying for those shorter and more efﬁcient
routes, there would be more chances for gaining unfamiliar and
unexpected precious experiences. This shows similarity to the pro-
cess toward the evolution of the artiﬁcial synthetic route of the tar-
get natural product. By keeping this endeavor, one may notice a
novel synthetic method that would be hard to get across without
trying to manage such synthetic challenges. Therefore, when onehas to deal with structurally complex molecules, serendipitous
discoveries emerge. It is also important to note that reaching to
the single summit of the highest peak is not always the purpose
of climbing the mountain. Walking along the ridge line of the
adjoining peaks of the mountain range has its own allure. Likewise,
the synthesis of an array of compounds with small structural
differences has its rich potential information. When combined,
information on those compounds is able to provide a detailed
structure–activity relationship, which would not be available from
a single-shot scrutiny of a certain molecule.1 The aim of those
divergent syntheses is the streamlined construction of a set of
invaluable compounds, which contrasts to the traditional target-
oriented linear or convergent synthesis (Fig. 1). One of the most
popular ideas of those kinds is called ‘Diversity-oriented synthe-
sis’.2 This idea was originally proposed by Schreiber and has
Figure 1. Schematic explanation of linear, convergent, and divergent synthesis.
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tual approach proposed by Danishefsky is named ‘Diverted total
synthesis’.3 This is an approach toward the preparation of a natural
product-like compound library by the derivatization of a versatile
synthetic intermediate. These concepts led to the successful ﬁnd-
ing of various bioactive compounds, which showcased its poten-
tials to reach the real drug candidate.4
It is natural to infer that these ramifying approaches have an
effect on the natural product synthesis. The original deﬁnition of
this ‘Divergent total synthesis’ approach was given by Boger to
be ‘the synthesis of at least two members of the class of com-
pounds’ from the common, advanced synthetic intermediate.5
Application of divergent synthesis could be encompassed even to
the groups of molecules with different family names. The method
with this widened applicability to several skeletons is what Mac-
Millan deﬁnes as ‘Collective total synthesis’.6 The syntheses that
could fall into this type seem to be gathering more and more atten-
tion.7 Upon planning the synthetic route to these projects, it is nec-
essary to set the pluripotent late-stage synthetic intermediate that
could transform into the array of the desired target families. In
most cases, those targets are in one or several biosynthetic families
that share the same biosynthetic intermediate. The mutual rela-
tionship among those target compounds, about appendage, stereo-
chemical or skeletal diversity, has a great inﬂuence on the strategy
chosen. The biosynthetic intermediates could be a candidate for
the common intermediate, but it is often difﬁcult to use thoseScheme 1. Baran’s synthesesnaturally occurring molecules as a synthetic intermediate. This is
because of the high polarity or instability that would not be com-
patible with most of the laboratory organic synthesis techniques.
Thus the selection of the one or several target molecules and
designing of the artiﬁcial common synthetic intermediate would
be the most signiﬁcant and difﬁcult points of the divergent way
of total synthesis.
This digest thus deals with the recent inspiring examples of nat-
ural product synthesis that deals with an appreciable collection of
biosynthetic relatives. With an emphasis on the strategy for choos-
ing the common intermediate, the potential of this productive
strategy will be discussed.
Divergent approach allows the streamlined syntheses of
biosynthetically similar natural products
Baran’s syntheses of eudesmane terpenes8
The construction of the core structure of certain family of
natural products, especially terpenes, could be made possible by
two-phase synthesis. The common carbon skeleton of the family
is synthesized ﬁrst by reducing the use of protective groups and
functionality-manipulating steps. This is followed by the introduc-
tion of hetero- or carbon-functionalities. Their approach was most
impressively presented in their syntheses of various eudesmane
terpenes by the diverse way of introducing oxygen functionality
to the common precursor dihydrojunenol (1) (Scheme 1). Diphe-
nylprolinol methyl ether-mediated enantioselective Michael–aldol
combination between 2 and 3 gives enone 4, followed by a side
chain introduction and Heck reaction to give 5. This was
transformed to dihydrojunenol (1) in a very efﬁcient manner via
1,4-addition and reduction on a gram scale. These eudesmane ter-
pene members with various oxidation states were biosynthesized
following these transformations via P450 oxidation. The regiose-
lectivity observed in Nature is usually difﬁcult to reproduce in lab-
oratory synthesis. The evolution of C–H oxidation procedure with
predictable regio- and chemoselectivity is thus necessary for exe-
cuting the diversiﬁed syntheses of this natural products family.
The oxidation of unactivated terpene C–H bond is made possible
by the functional group-tethered method. One is the TFDO
(methyl(triﬂuoromethyl)dioxirane)-mediated C–H oxidation that
regioselectively oxidizes the C–H bond within the bicyclic core
structure. Interestingly, C–H bromination by Hofmann–Löfﬂer–
Freytag (HLF) reaction, the other C–H functionalization process
they employed, mediated the functionalization of the other C–Hof eudesmane alkaloids.
Scheme 2. Fukuyama’s syntheses of all the amathaspiramides.
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tion procedures and 1,2-directed oxidation methodology, various
eudesmane terpenoids were synthesized one after the other. From
the triﬂuoroethyl carbamate 6, the intrinsic difference in the selec-
tivity of transformations emerges. The reaction with TFDO pro-
motes the inward oxygenation to afford 7, providing 4-epiajanol
(8) in a single step. HLF reaction oxidizes outwards instead. Bro-
mine atom on 9was substituted intramolecularly and gave dihydr-
oxyeudesmane (10) shortly. The combination of these two recipes
was also possible in regioselective manner. Through the doubly
oxidized intermediate 11, pygmol (12) and eudesmanetetraol
(13) were synthesized. The indispensable point of the success of
this divergent synthesis is the ﬁnding of predictable, regioselective,
and orthogonal methodology for introduction of oxygen function-
ality on this skeleton. This synthesis underscores the importance
and necessity of the development of selective and predictive meth-
odology of C–H activation transformation.
Fukuyama’s syntheses of all the amathaspiramides9
Targets of these divergent strategies include the syntheses of
co-isolated natural products bearing partial variation. amathaspi-
ramide alkaloids A–F (14–19) differ in the oxidation state of the left
side pyrrolidine ring, while F (19) is also typical for an epimeriza-
tion at the cyclic hemiaminal moiety (Scheme 2). Each of these
compounds shares the same skeleton. Thus, it would be necessaryScheme 3. Movassaghi’s syntto ﬁnd out the pluripotent late-stage intermediate for the compre-
hensive syntheses of all the members of this family. To this end, an
appropriate methodology was required to make this idea possible.
In this case, the envisioned transformation does not mimic the Nat-
ure’s transformation order that gradually increases the oxidation
state. It is characteristic to employ the gradual reductions from
the most oxidized amathaspiramide D (17) as the common precur-
sor to all the other members of this family. Cyclic imide intermedi-
ate 20 was synthesized in 8 steps from butenolide 21 via
asymmetric hydrogenation followed by alpha-functionalization,
formation of imide and bromination. Interestingly, reduction with
DIBAL mediated the regio- and diastereoselective transformation
to give Amathaspiramide D (17). The key point was the reduction
of lactam in 17 to cyclic imine, E (18), mediated by Schwartz
reagent (Cp2ZrHCl). This relatively rare and chemoselective trans-
formation was the key to the success of the diversiﬁcation in this
project. Cyclic imine was converted to the corresponding second-
ary and tertiary amines C (16) and A (14). An interesting point is
the exceptional stability of the stereochemistry of the hemiaminal
to various reaction conditions. Cyclic hemiaminal moiety was then
successfully epimerized under the basic reaction conditions to give
F (19). With B (15) synthesized from D (17), all the known mem-
bers of amathaspiramides were efﬁciently obtained. This example
indicates the importance of getting insight into the chemical rela-
tionship between the selected target compounds and ﬁnding their
intrinsic reactivities from it.heses of all agelastatins.
Scheme 4. Li’s syntheses of Taiwaniaquinols and Taiwaniaquinones.
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Sometimes the synthesis of natural product is much simpler
than it looks to be. This is because certain stereocenters in natural
products are controlled by following the simplest and most efﬁ-
cient route that favors a naturally occurring stereochemistry. Con-
trol of the diastereochemistry in natural product synthesis could
thus be envisioned by mimicking the biosynthetic route. This ret-
robiosynthetic approach was successfully applied to the Mov-
assaghi’s syntheses of all agelastatins (Scheme 3). The synthesis
started with D-aspartic acid-derived pyrrole 22. The cyclopentane
moiety was constructed from intermediate 23, through stereose-
lective cyclization from the imidazolone moiety to acyl iminium
intermediate, which gave agelastatin A (24) in short steps. Bromin-
ation and aminal exchange of A (24) give B (25) and E (26) respec-
tively. Similarly, more oxidized member agelastatin C (27) is
synthesized from the same intermediate 23 via dihydroxylation
of dehydrated imidazolone 28. N-Demethylated members, agelast-
atin D (29) and F (30) was also synthesized from the corresponding
demethylated imidazolone via 31. As such, all agelastatin members
with the same core skeleton, on various brominated or oxygenated
states were synthesized. The key to this synthesis was the employ-
ment of artiﬁcial imidazolone moiety as the alternative potent and
manipulable nucleophile, which corresponds to imidazole unit in
natural biosynthesis. The stereochemistry of the cyclization from
imidazolone was accordingly controlled by the inherent tendency
of the molecule to choose the natural stereochemistry. This simple
and brilliant solution of the stereochemical induction made it pos-
sible to synthesize family natural products in a uniﬁed approach.Scheme 5. Baran’s synthesLi’s syntheses of Taiwaniaquinols and Taiwaniaquinones11
Meroterpenoids are natural products containing both of the
units of terpene and polyketide. They are known to possess various
similar families with variable oxidation states. These molecules are
attractive targets for divergent synthetic approach (Scheme 4). The
construction of core structure was realized by Bi(OTf)3-catalyzed
cyclization of chain intermediate 32 that effected the diastereose-
lective construction of bicyclo[4.4.2]decane unit 33. Subsequent
ring contraction strategy employing Wolff rearrangement efﬁ-
ciently gave the 6-5-6 ring system of 34 that is common to these
natural products. Transformation of the versatile formyl moiety
was the key to the diversiﬁcation of the fate of the route. Epimer-
ization of the stereochemistry of aldehyde in 34 gave 35. From this
intermediate, oxidation of phenol moiety furnished Taiwaniaqui-
none F (36) and A (37). Conversion to the unsaturated aldehyde
by Ito–Saegusa oxidation afforded Taiwaniaquinol D (38). Also, oxi-
dative removal of C-1 formyl unit and demethylation of phenol
moiety furnished Taiwaniaquinol B (39). The choice of the struc-
ture of the common intermediate 34 is understandable from the
viewpoint of utilizing the facile construction of six-membered ring
and possible transformation to the necessary ﬁve-membered moi-
ety with versatile formyl group. This collective synthesis under-
scores the importance of the selection of the versatile common
intermediate and rapid construction of it, which does not necessar-
ily imitate the biosynthetic pathway. For those syntheses, discov-
ery of connection between molecules that could be tied with
truly artiﬁcial transformations is the key to the breakthrough to
the fruitful synthetic scheme.es of meroterpenoids.
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As already seen above, introduction of various functional groups
on the common skeleton of a natural product group affords a
focused library of a certain structure motif. Likewise, assemblage
of the core skeletons of several resembling natural product families
from a single common intermediate offers even more considerable
opportunities for the preparation of a broad range of drug leads.
Examples of this potential strategy would show how the transfor-
mations should be planned for diversiﬁcation purpose. The core
structures of certain meroterpenoid families resemble each other.
Those skeletons could be considered as the combination of the
unchanged core and the ﬂanking carbon scaffolds as the substitu-
tion. Baran group succeeded in setting a new potential intermedi-
ate borono-sclareolide 40 and applied to the divergent total
synthesis of various meroterpenoid natural products (Scheme 5).
The idea stems from the fact that these natural products have dif-
ferences mostly on aromatic moiety and have much in common on
terpene part. Their synthesis started from the preparation of
borono-sclareolide 40 that bears boronic acid moiety in place of
the lactone unit of commercially available and inexpensive sclareo-
lide (41) (ca. $5/gram). This compound was thus subjected to the
removal of one carbon unit to give the versatile boronic lactone
intermediate 40. This intermediate was subjected to Suzuki–
Miyaura coupling reaction and afforded dictyvaric acid (42) after
deprotection. The reactivity of 40 was also found in radical
coupling reaction with quinone under the K2S2O8–silver nitrate
reagent combination, which gave the cyclized product chromazo-
narol (43). More oxidized relatives were synthesized by employing
various oxidative transformations known for hydroquinone-type
intermediate. Thus, para-alkyl hydroquinone was oxidized with
NaIO4 to give the para-quinone, yahazunone (44) that could then
be reduced to give the hydroquinone, yahazunol (45). Different
oxidative transformations of 43 afforded the ortho-quinone that
constitutes the synthesis of (+)-8-epi-puupehedione (46). As such,
uniﬁed synthetic route was developed to several meroterpenoids
with the same substructure from the new versatile precursor 40.
The reason for the success of this strategy lies in focusing on the
easily available terpenoid unit feedstock and application of the
one-carbon lacking boronic lactone intermediate. This versatile
reactivity in various coupling reactions to aromatic moiety would
have been a difﬁcult transformation from natural sclareolide itself.
Boger’s divergent syntheses of Kopsia alkaloids13
The idea ‘Divergent Total Synthesis’ was ﬁrst introduced by
Boger in their synthesis of azaﬂuoranthene alkaloids.5 This
approach is deﬁned as the synthesis of at least two members ofScheme 6. Boger’s synthesthe class of compounds from the common, advanced synthetic
intermediate. Thus it was most effectively applied to the natural
product group with many family members. As their group have
already devised many synthetic application of their [4+2]/[3+2]
cycloaddition cascade of 1,3,4-oxadiazole for the construction of
the late stage core structure of Aspidosperma alkaloids, they
accordingly applied this cascade strategy to the more bridged fam-
ily, Kopsia alkaloids (Scheme 6). The common intermediate 47was
designed to maximize the number of biogenetically close synthetic
targets. The key cascade substrate 48 was equipped with the
terminal C21 silyloxy group for transannular bond-forming. It
was applied to the [4+2]/[3+2] cycloaddition cascade at 180 C in
o-dichlorobenzene and furnished the pentacyclic intermediate as
a common intermediate. To assemble the structure of the Kopsia
alkaloids, oxa-bridge was removed to give conjugated ester 49.
After the conversion of terminal silyloxy group to xanthate, it
was subjected to intramolecular radical conjugate addition to
unsaturated ester. This promptly furnished the desired structure
of ()-kopsinine (50). From the substrate with Cbz (51) in place
of Bn group, cyclization was performed with silyloxy unit as the
latent leaving group for transannular enamide alkylation. This
afforded indolenine intermediate that was reduced to give kopsif-
oline H (52). Similar transformation from the unsaturated sub-
strate 53 gave ()-kopsifoline D (54). Compound 53 could also
be applied to the oxa-Michael reaction to eventually furnish the
()-deoxoapodine (55). Kopsia alkaloids thus obtained along these
courses would constitute the results of various cyclization modes
from the C21-functionalized Aspidosperma alkaloid core structure,
which should also be along the biogenetic scheme for those
compounds.
MacMillan’s syntheses of several families of indole alkaloids6
Application of divergent synthesis could be encompassed even
to the groups of molecules with different family names. This
widened applicability of the method to several skeletons is what
MacMillan deﬁnes as ‘Collective Total Synthesis’.6 Their approach
is the combination of organocascade catalysis to the versatile
intermediate and application of them to various carbon-unit intro-
ducing transformations (Scheme 7). By the employment of the
organocatalyst 56 that enables the construction of the quaternary
stereogenic center from propynal 57 and indole 58, subsequent
intramolecular aza-Michael reaction afforded the key intermediate
59 or 60. These molecules equip with the common structural motif
of many families of indole alkaloids. Thus ﬂexible attaching strat-
egy of various subunits enables an easy access to various natural
product relatives. As shown in the scheme, route to Aspidosperma
alkaloids is forged by the allylation of the secondary amine to givees of Kopsia alkaloids.
Scheme 7. MacMillan’s syntheses of several families of indole alkaloids.
Scheme 8. Oguri’s syntheses of biologically related indole alkaloids.
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carbon–carbon double bonds. This transformation gives aspidospe-
rmidine (62) that was further transformed to vincadifformine (63)
in two steps. Similarly, allylation to 64 and Heck cyclization reac-
tion from the substrate 65 afforded the strychnine (66) with very
short synthetic route. Kopsia alkaloids differ from the above com-
pounds in bearing the bicyclo[2.2.2]octane unit. For the construc-
tion of the core skeleton, they employed a Diels–Alder strategy.
Thus, for the Diels–Alder cyclization strategy for the 6-membered
ring, diene unit in 67was constructed via Wittig reaction. This pro-
cedure enabled the synthesis of kopsinine (68) that was further
transformed to kopsanone (69) via the known sequence. As seen
from these fruitful results, collective approaches to the family com-
pounds allowed the efﬁcient syntheses.
Oguri’s syntheses of biogenetically related indole alkaloids14
Monoterpenoid indole alkaloids have often been chosen as the
synthetic targets of natural product synthesis. These alkaloids con-
stitute a very big family because they are biosynthesized by a verysimilar manifold from the common precursors, tryptamine and
secologanin. It is thus reasonable to say that a uniﬁed synthetic
proposal to access all of these molecules should exist. Oguri et al.
successfully illustrated the possibility of this divergent proposal
in a laboratory synthesis (Scheme 8). The biggest obstacle for real-
izing this divergent synthetic proposal is supposed to be the design
and the construction of the key intermediate by taming a highly
reactive cyclic amino diene structure found in the natural interme-
diate 70. They newly designed the stabilized intermediate 71 and
employed the cyclization reaction from amide/alkyne 72 for the
temporary preparation of the reactive and yet sufﬁciently stable
intermediate equipped with electron-withdrawing substituent on
the diene moiety. They developed the copper-catalyzed cyclization
conditions utilizing [Cu(dppf)(MeCN)]PF6 as the very mild and
effective catalyst for the construction of this motif. The reaction
was fast and the product intermediate was found applicable to
the next reaction without isolation. Owing to the presence of the
electron-withdrawing group on the diene in 71, hydrogenation of
one of the dienes was realized. This was then subjected to the
intramolecular Diels–Alder reaction for the construction of the
6162 J. Shimokawa / Tetrahedron Letters 55 (2014) 6156–6162main structure of the Aspidosperma alkaloid 73, and this helped
the accomplishment of the total synthesis of aspidospermidine
(74). Deprotection and the silyl enolate formation set the stage
for Diels–Alder reaction with a different connection mode that
facilitates the diastereoselective formation of the andranginine
(75). Simple heating of the key intermediate 71 mediated the yet
different mode of Diels–Alder reaction, that realized the construc-
tion of catharanthine derivative 76, that is easily transformed to
catharanthine (77). They also succeeded in the formation of other
families of these indole alkaloids, including andrangine-type,
ngouniensine-type and even to the unnatural-type, under various
reaction conditions. This variety-promoting synthesis strongly
indicates the power of biosynthetically inspired synthesis for the
focused preparation of the bunch of family natural products. Nev-
ertheless, this achievement implies that the application of this
diversiﬁcation strategy requires cautious selection of the late stage
intermediate that is synthetically manipulable. Thus the synthesis
introduced here should be considered as the monumental achieve-
ment for the biosynthetically inspired synthesis of natural
products.
Conclusion
It is always desirable if one approach to total synthesis of natu-
ral product is easily applied to the similar, biosynthetically, and
structurally related compounds. From this point, diversiﬁcation
strategy itself is a simple and atypical idea. Even so, the realization
of this idea is not simple. You need to be cautious and well planned
for the efﬁcient diversiﬁcation. The structure of the group of natu-
ral products could thus be strategically distinguished into two
parts: common structural part and the alternating ones. This
demands simplicity and diversity, opposite requirements, which
apparently restrict the possible strategies taken toward the synthe-
sis. Nevertheless, this limitation seems to cast light on the chal-
lenges we have to cope with, for more efﬁcient synthesis and the
development of the novel transformation. In this digest, several
strategies that fall in those criteria were presented. One strategy
is following the natural biosynthetic transformation that takes
advantage of the inherent stereoselectivity of the reaction (2.1,
2.3, 2.8). This strategy offers challenges for the development of
unprecedented reaction which Nature itself is utilizing. Another
strategy utilizes the knowledge about how Nature is doing during
the diversiﬁcation of natural products. One can accordingly pull
out a novel idea from the similarity about how to synthetically
connect each of the compounds with innovative transformations
(2.2, 2.4, 2.5, 2.6, 2.7). From the examples shown, a focused synthe-
sis planning of a group of compounds allows the rapid access to the
ramifying results within the natural product synthesis. Variousapproaches to compound libraries with diversity-oriented method-
ology are more and more anticipated. Findings from these diversi-
ﬁcation strategies are expected to give more andmore contribution
to the diverse drug development to which more and more new
ideas can contribute. These progresses would also be expected to
pave the road for new ﬁndings on biological activity, chemical
transformation methodologies, and new drugs.
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